CAPR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Capricor Therapeutics is not a clear buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has a meaningful FDA catalyst coming up, but the current technical setup is weak, analyst targets were cut, and recent executive selling adds caution. I would not buy aggressively at this price; the better call is to hold and wait for clearer confirmation after the FDA decision or a stronger trend reversal.
CAPR is trading at 23.31, just above the S1 support level of 23.539 and below the pivot level of 26.748, which means price is sitting in a weak zone under resistance. MACD histogram is -0.401 and negatively expanding, showing bearish momentum. RSI_6 at 25.775 is oversold/very weak, but not enough alone to confirm a reversal. Moving averages are converging, which suggests the stock is at an inflection point, but the current trend is still fragile. The stock trend model suggests limited near-term upside and slight weakness over the next week and month.
Positive catalysts include the July 29 FDA advisory committee meeting for Deramiocel, which is a major event-driven catalyst, and the recent Hope-2 extension data showing Deramiocel may slow disease progression over five years with stable cardiac function and a favorable safety profile. Analysts still maintain a Buy rating despite lowering price targets, and there is optimism around potential approval in Q3 and a Priority Review Voucher sale in Q4.
Capricor executives sold about 48,200 shares for roughly $1.46 million ahead of the FDA review, which is a negative sentiment signal. The stock also recently declined 12.11%, and technical momentum remains weak.
No latest quarter financial snapshot was provided, so there is no direct quarter-over-quarter revenue or earnings assessment available. Based on the data given, the key financial story is not operating results but pipeline-driven value, with the market focused on Deramiocel approval timing and potential commercialization rather than current profitability trends.
Recent analyst action is still constructive but less optimistic than before: Roth Capital kept a Buy rating but lowered the price target to $38 from $43. The firm remains positive on approval and a possible Priority Review Voucher sale, but it also pushed back the expected U.S. launch and removed a milestone from its model. Wall Street pros appear generally bullish on the pipeline, but the tone has turned more cautious on timing and monetization.
